ENTA · Categories · Form 4

ENTA - SEC Form 4 insider transactions

Enanta Pharmaceuticals Inc. (ENTA) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for ENTA

• 86d
  SEC Form 4 filed by Director Vance Terry

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 86d
  SEC Form 4 filed by Director Russell Lesley

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 86d
  SEC Form 4 filed by Director Peterson Kristine

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 86d
  SEC Form 4 filed by Director Hata Yujiro S

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 86d
  SEC Form 4 filed by Director Foletta Mark G

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 86d
  SEC Form 4 filed by Director Carter Bruce L A

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 114d
  Chief Legal Officer Kowalsky Matthew Paul was granted 5,493 shares and covered exercise/tax liability with 1,902 shares (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 114d
  Chief Business Officer Luu Brendan covered exercise/tax liability with 3,257 shares and was granted 6,562 shares, increasing direct ownership by 9% to 41,634 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 114d
  Chief Product Strategy Officer Kieffer Tara Lynn was granted 6,562 shares and covered exercise/tax liability with 3,257 shares, increasing direct ownership by 11% to 33,925 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 114d
  Chief Medical Officer Rottinghaus Scott T. was granted 6,875 shares and covered exercise/tax liability with 3,413 shares, increasing direct ownership by 16% to 25,254 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 114d
  Chief Scientific Officer Or Yat Sun was granted 6,875 shares and covered exercise/tax liability with 3,413 shares, increasing direct ownership by 0.93% to 374,854 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 114d
  President and CEO Luly Jay R. was granted 20,000 shares and covered exercise/tax liability with 6,155 shares, increasing direct ownership by 2% to 871,871 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 183d
  Officer Capps Kathleen S. sold $4,596 worth of shares (323 units at $14.23), decreasing direct ownership by 4% to 8,377 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 183d
  Officer Trout Harry R. Iii sold $7,713 worth of shares (542 units at $14.23), decreasing direct ownership by 3% to 16,348 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 183d
  Chief Medical Officer Rottinghaus Scott T. sold $11,356 worth of shares (798 units at $14.23), decreasing direct ownership by 4% to 21,792 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 183d
  Chief Business Officer Luu Brendan sold $19,837 worth of shares (1,394 units at $14.23), decreasing direct ownership by 4% to 38,329 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 183d
  Chief Product Strategy Officer Kieffer Tara Lynn sold $29,968 worth of shares (2,106 units at $14.23), decreasing direct ownership by 6% to 30,620 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 183d
  Chief Scientific Officer Or Yat Sun sold $34,010 worth of shares (2,390 units at $14.23), decreasing direct ownership by 0.64% to 371,392 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 183d
  President and CEO Luly Jay R. sold $67,493 worth of shares (4,743 units at $14.23), decreasing direct ownership by 0.55% to 858,026 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 186d
  SEC Form 4 filed by Enanta Pharmaceuticals Inc.

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 186d
  SEC Form 4 filed by Enanta Pharmaceuticals Inc.

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 186d
  Chief Business Officer Luu Brendan covered exercise/tax liability with 498 shares, decreasing direct ownership by 1% to 39,723 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 186d
  Chief Product Strategy Officer Kieffer Tara Lynn covered exercise/tax liability with 753 shares, decreasing direct ownership by 2% to 32,726 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 186d
  Chief Scientific Officer Or Yat Sun covered exercise/tax liability with 753 shares, decreasing direct ownership by 0.20% to 373,782 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 186d
  President and CEO Luly Jay R. covered exercise/tax liability with 1,885 shares, decreasing direct ownership by 0.22% to 862,769 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 192d
  Officer Capps Kathleen S. was granted 3,163 shares, increasing direct ownership by 54% to 8,992 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 193d
  Officer Trout Harry R. Iii was granted 6,463 shares, increasing direct ownership by 59% to 17,375 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 193d
  SEC Form 4 filed by Chief Business Officer Luu Brendan

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 193d
  SEC Form 4 filed by Chief Product Strategy Officer Kieffer Tara Lynn

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 193d
  SEC Form 4 filed by Chief Legal Officer Kowalsky Matthew Paul

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 193d
  SEC Form 4 filed by Chief Medical Officer Rottinghaus Scott T.

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 193d
  SEC Form 4 filed by Chief Scientific Officer Or Yat Sun

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 193d
  SEC Form 4 filed by President and CEO Luly Jay R.

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 303d
  Chief Medical Officer Rottinghaus Scott T. covered exercise/tax liability with 2,217 shares, decreasing direct ownership by 9% to 22,590 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 450d
  SEC Form 4 filed by Director Vance Terry

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 450d
  SEC Form 4 filed by Director Russell Lesley

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 450d
  SEC Form 4 filed by Director Peterson Kristine

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 450d
  SEC Form 4 filed by Director Hata Yujiro S

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 450d
  SEC Form 4 filed by Director Foletta Mark G

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 450d
  SEC Form 4 filed by Director Carter Bruce L A

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 478d
  Chief Business Officer Luu Brendan was granted 7,500 shares and covered exercise/tax liability with 3,326 shares, increasing direct ownership by 12% to 40,221 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 478d
  Chief Product Strategy Officer Kieffer Tara Lynn was granted 7,500 shares and covered exercise/tax liability with 3,326 shares, increasing direct ownership by 14% to 33,479 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 478d
  Chief Medical Officer Rottinghaus Scott T. was granted 9,750 shares and covered exercise/tax liability with 2,861 shares, increasing direct ownership by 38% to 24,807 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 478d
  Chief Scientific Officer Or Yat Sun was granted 9,750 shares and covered exercise/tax liability with 4,324 shares, increasing direct ownership by 1% to 374,535 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 478d
  Chief Fin. & Admin Officer Mellett Paul J was granted 7,500 shares and covered exercise/tax liability with 3,326 shares, increasing direct ownership by 5% to 95,884 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 478d
  President and CEO Luly Jay R. was granted 25,500 shares and covered exercise/tax liability with 7,484 shares, increasing direct ownership by 2% to 864,654 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 544d
  Chief Product Strategy Officer Kieffer Tara Lynn sold $18,401 worth of shares (2,283 units at $8.06), decreasing direct ownership by 7% to 29,305 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 544d
  Chief Business Officer Luu Brendan sold $18,401 worth of shares (2,283 units at $8.06), decreasing direct ownership by 6% to 36,047 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 544d
  Chief Medical Officer Rottinghaus Scott T. sold $6,980 worth of shares (866 units at $8.06), decreasing direct ownership by 5% to 17,918 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 544d
  Chief Scientific Officer Or Yat Sun sold $20,883 worth of shares (2,591 units at $8.06), decreasing direct ownership by 0.70% to 369,109 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 544d
  Chief Fin. & Admin Officer Mellett Paul J sold $20,883 worth of shares (2,591 units at $8.06), decreasing direct ownership by 3% to 91,710 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 544d
  President and CEO Luly Jay R. sold $41,445 worth of shares (5,142 units at $8.06), decreasing direct ownership by 0.64% to 801,638 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 550d
  Chief Business Officer Luu Brendan covered exercise/tax liability with 753 shares, decreasing direct ownership by 2% to 38,330 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 550d
  Chief Product Strategy Officer Kieffer Tara Lynn covered exercise/tax liability with 753 shares, decreasing direct ownership by 2% to 31,588 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 550d
  Chief Scientific Officer Or Yat Sun covered exercise/tax liability with 1,595 shares, decreasing direct ownership by 0.43% to 371,700 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 550d
  Chief Fin. & Admin Officer Mellett Paul J covered exercise/tax liability with 1,595 shares, decreasing direct ownership by 2% to 94,301 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 550d
  President and CEO Luly Jay R. covered exercise/tax liability with 3,829 shares, decreasing direct ownership by 0.47% to 806,780 units (SEC Form 4)

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 557d
  SEC Form 4 filed by Chief Legal Officer Kowalsky Matthew Paul

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 557d
  SEC Form 4 filed by Chief Business Officer Luu Brendan

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
• 557d
  SEC Form 4 filed by Chief Product Strategy Officer Kieffer Tara Lynn

  4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

Other ENTA categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends